[1]
|
W. M. Kuehl and P. L. Bergsagel, “Multiple Myeloma: Evolving Genetic Events and Host Interactions,” Nature Reviews Cancer, Vol. 2, No. 3, 2002, pp. 175-187.
doi:10.1038/nrc746
|
[2]
|
M. C. Minnema, E. van der Spek, N. W. C. J van de Donk and H. M. Lokhorst, “New Developments in the Treatment of Patients with Multiple Myeloma,” The Netherlands Journal of Medicine, Vol. 68, No. 1, 2010, pp. 24-32.
|
[3]
|
H. Kaufman, E. Urbauer, J. Ackermann, H. Huber and J. Drach, “Advances in the Biology and Therapeutic Management of Multiple Myeloma,” Annals of Hematology, Vol. 80, No. 8, 2001, pp. 445-451.
doi:10.1007/s002770100348
|
[4]
|
T. K. H. Chang, G. F. Weber, C. L. Crespi and D. J. Waxman, “Differential Activation of Cyclophosphamide and Ifosphamide by Cytochromes P-450 2B and 3A in Human Liver Microsomes,” Cancer Research, Vol. 53, No. 23, 1993, pp. 5629-5637.
|
[5]
|
T. Lang, K. Klein, J. Fischer, A. K. Nussler, P. Neuhaus, U. Hofmann, et al., “Extensive Genetic Polymorphism in the Human CYP2B6 Gene with Impact on Expression and Function in Human Liver,” Pharmacogenetics, Vol. 11, No. 7, 2001, pp. 399-415.
doi:10.1097/00008571-200107000-00004
|
[6]
|
J. Kirchheiner, C. Klein, I. Meineke, J. Sasse, U. M. Zanger, T. E. Murdter, et al., ”Bupropion and 4-OH-bupropion Pharmacokinetics in Relation to Genetic Polymorphisms in CYP2B6,” Pharmacogenetics, Vol. 13, No. 10, 2003, pp. 619-626. doi:10.1097/00008571-200310000-00005
|
[7]
|
K. Tsuchiya, H. Gatanaga, N. Tachikawa, K. Teruya, Y. Kikuchi, M. Yoshino, et al., “Homozygous CYP2B6 *6 (Q172H and K262R) correlates with High Plasma Efavirenz Concentrations in HIV-1 Patients Treated with Standard Efavirenz-Containing Regimens,” Biochemical and Biophysical Research Communications, Vol. 319, No. 4, 2004, pp. 1322-1326. doi:10.1016/j.bbrc.2004.05.116
|
[8]
|
M. Nakajima, S. Komagata, Y. Fujiki, Y. Kanada, H. Ebi, K. Itoh, et al., “Genetic Polymorphisms of CYP2B6 Affect the Pharmacokinetics/Pharmacodynamics of Cyclophosphamide in Japanese Cancer Patients,” Pharmacogenetics and Genomics, Vol. 17, No. 6, 2007, pp. 431-445.
doi:10.1097/FPC.0b013e328045c4fb
|
[9]
|
M. H. Hofmann, J. K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, et al., “Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T (Q172H), a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 325, No. 1, 2008, pp. 284-292.
doi:10.1124/jpet.107.133306
|
[10]
|
J. Seidegard, W. R. Vorachek, R. W. Pero and W. R. Pearson, “Hereditary Differences in the Expression of the Human Glutathione Transferase active on Trans-Stilbene Oxide Are Due to a Gene Deletion,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 85, No. 19, 1988, pp. 7293-7297.
doi:10.1073/pnas.85.19.7293
|
[11]
|
S. Pemble, R. Klaus, K. R. Schroeder, S. R. Spencer, D. J. Meyer, E. Hallier, et al., “Human Glutathione S-Transferase Theta (GSTT1): cDNA Cloning and the Characterization of a Genetic Polymorphism,” The Biochemical Journal, Vol. 300, No. 1, 1994, pp. 271-276.
|
[12]
|
D. A. Bell, J. A. Taylor, D. F. Paulson, C. N. Robertson, J. L. Mohler and G. W. Lucier, “Genetic Risk and Carcinogen Exposure: A Common Defect of the Carcinogen-Metabolism Gene Glutathione S-Transferase M1 (GSTM1) That Increases Susceptibility to Bladder Cancer,” Journal of the National Cancer Institute, Vol. 85, No. 14, 1993, pp. 1159-1164. doi:10.1093/jnci/85.14.1159
|
[13]
|
A. Ahmadi, P. Jonsson, U. Flodin and P .Soderkvist, ”Interaction between Smoking and Glutathione S-Transferase Polymorphisms in Solvent-Induced Chronic Toxic Encephalopathy,” Toxicology and Industrial Health, Vol. 18, No. 6, 2002, pp. 289-296.
doi:10.1191/0748233702th152oa
|
[14]
|
T. M. Ishimoto and F. Ali-Osman, “Allelic Variants of the Human Glutathione S-Transferase P1 Gene Confer Differential Cytoprotection against Anticancer Agents in Escherichia coli,” Pharmacogenetics, Vol. 12, No. 7, 2002, pp. 543-553. doi:10.1097/00008571-200210000-00006
|
[15]
|
A.-S. Johansson, G. Stenberg, M. Widersten and B. Mannervik, “Structure-Activity Relationships and Thermal Stability of Human Glutathione Transferase P1-1 Governed by the H-Site Residue 105,” Journal of Molecular Biology, Vol. 278, No. 3, 1998, pp. 687-698.
doi:10.1006/jmbi.1998.1708
|
[16]
|
M. Rohrbacher, A. Kirchhof, G. Geisslinger and J. Lotsch, “PyrosequencingTMBased Screening for Genetic Polymorphisms in Cytochrome P450 2B6 of Potential Clinical Relevance,” Pharmacogenomics, Vol. 7, No. 7, 2006, pp. 995-1002. doi:10.2217/14622416.7.7.995
|
[17]
|
J. Bray, J. Sludden, M. J. Griffin, M. Cole, M. Verril, D. Jamieson, et al., “Influence of Pharmacogenetics on Response and Toxicity in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide,” British Journal of Cancer, Vol. 102, No. 6, 2010, pp. 1003-1009.
doi:10.1038/sj.bjc.6605587
|
[18]
|
N. A. Hesby, C.-Y. Hui, M. A. Goldthorpe, J. K. Colle, M. C. Soh, P. J. Gow, et al., “The Combined Impact of CYP2C19 and CYP2B6 Pharmacogenetics on Cyclophosphamide Bioactivation,” British Journal of Clinical Pharmacology, Vol. 70, No. 6, pp. 844-853.
doi:10.1111/j.1365-2125.2010.03789.x
|
[19]
|
H. Xie, L. Griskevicius, L. Stahle, Z. Hassan, U. Yasara, A. Rane, et al., “Pharmacogenetics of Cyclophosphamide in Patients with Hematological Malignancies,” European Journal of Pharmaceutical Sciences, Vol. 27, No. 1, 2006, pp. 54-61.
|
[20]
|
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, et al., “Genetic Abnormalities and Survival in Multiple Myeloma: The Experience of the Intergroupe Francophone du Myelome,” Blood, Vol. 109, No. 8, 2007, pp. 3489-3495.
doi:10.1182/blood-2006-08-040410
|
[21]
|
R. K. Dasgupta, P. J. Adamson, F. E. Davies, S. Rollinson, P. L. Roddam, A. J. Ashcroft, et al., “Polymorphic Variation in GSTP1 Modulates Outcome Following Therapy for Multiple Myeloma,” Blood, Vol. 102, No. 7, 2003, pp. 2345-2350. doi:10.1182/blood-2003-02-0444
|
[22]
|
C. Sweeney, G. Y. McClure, M. Y. Fares, A. Stone, B. F. Coles, P. A. Thompson, et al., “Association between Survival after Treatment for Breast Cancer and Glutathione S-Transferase P1 Ile105Val Polymorphism,” Cancer Research, Vol. 60, No. 20, 2000, pp. 5621-5624.
|
[23]
|
A. Beeghly, D. Katsaros, H. Chen, S. Fracchioli, Y. Zhang, M. Massobrio, et al., “Glutathione S-Transferase Polymorphisms and Ovarian Cancer Treatment and Survival,” Gynecologic Oncology, Vol. 100, No. 2, 2006, pp. 330-337. doi:10.1016/j.ygyno.2005.08.035
|
[24]
|
A. V. Khrunin, A. Moisseev, V. Gorbunova and S. Limborska, “Genetic Polymorphisms and the Efficacy and Toxicity of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients,” Pharmacogenomics Journal, Vol. 10, No. 1, 2010, pp. 54-61. doi:10.1038/tpj.2009.45
|
[25]
|
V. Maggini, G. Buda, S. Galimberti, E. Conidi, N. Giuliani, F. Morabito, et al., “Response to Chemotherapy and Tandem Autologous Transplantation of Multiple Myeloma Patients and GSTP1 and TYMS Polymorphisms,” Leukemia Research, Vol. 32, No. 1, 2008, pp. 49-53.
doi:10.1016/j.leukres.2007.03.029
|